VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has begun cell line development for its lead BiTAC® T-cell engager program, marking another step in preparing the company’s most advanced oncology candidate for future clinical development. The company announced that it has selected ATUM, a U.S.-based contract research organization specializing in bioengineering and cell line development, to generate stable clonal cell lines using its proprietary Leap-In Transposase® technology.
The collaboration represents an important development milestone, supporting manufacturing, analytical development and nonclinical studies required before clinical testing. ATUM will apply its Leap-In Transposase® technology to generate stable clonal cell lines for VERAXA’s lead therapeutic candidate. According to VERAXA, the collaboration is intended to advance the candidate toward IND/CTA-enabling studies.
VERAXA’s BiTAC® platform is designed to improve the selectivity of T-cell engagers, potentially reducing toxicity associated with conventional approaches. The company recently expanded its research facilities in Heidelberg, Germany, increasing laboratory capacity as multiple oncology programs move toward clinical development.
Investors can access the latest news and updates relating to VRXA in the company’s newsroom at https://ibn.fm/VRXA. For full terms of use and disclaimers, please refer to the InvestorBrandNetwork website at http://IBN.fm/Disclaimer.
Forward-looking statements in this article involve risks and uncertainties that may cause actual results to differ materially. These forward-looking statements are subject to a number of risks and uncertainties, including those set forth under "Risk Factors" in the Company's most recent Annual Report on Form 10-K and other filings with the SEC. Undue reliance should not be placed on these forward-looking statements, and the Company undertakes no duty to update this information unless required by law.
